骨骼病变为首发表现的急性淋巴细胞白血病1例

Abstract
Figure/Table
References
Related Citation (0)

[1]	秘营昌.中国成人急性淋巴细胞白血病诊断与治疗专家共识——诊断和预后分组解读[J].中华血液学杂志,2013,34(11):994-996.
[3]	袁田,秘营昌.成年人急性淋巴细胞白血病基因组学研究进展[J].国际输血及血液学杂志,2012,35(6): 521-524.
[4]	中国医师协会血液科医师分会,中华医学会血液学分会,中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订)[J].中华内科杂志, 2013,52(9): 791-795.
[2]	Swerdlow S H, Campo E, Harris N L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [M]. Lyon: Iarc Press, 2008:167-178.
[5]	Riccio I, Marcarelli M, Del Regno N, et al. Musculoskeletal problems in pediatric acute leukemia[J]. J Pediatr Orthop B, 2013, 22(3): 264-269.
[3]	袁田,秘营昌.成年人急性淋巴细胞白血病基因组学研究进展[J].国际输血及血液学杂志,2012,35(6): 521-524.
[6]	Ganesan P, Thulkar S, Gupta R, et al. Childhood aleukemic leukemia with hypercalcemia and bone lesions mimicking metabolic bone disease [J]. J Pediatr Endocrinol Metab, 2009, 22(5): 463-467.
[4]	中国医师协会血液科医师分会,中华医学会血液学分会,中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订)[J].中华内科杂志, 2013,52(9): 791-795.
[5]	Riccio I, Marcarelli M, Del Regno N, et al. Musculoskeletal problems in pediatric acute leukemia[J]. J Pediatr Orthop B, 2013, 22(3): 264-269.
[7]	Kawedia J D, Kaste S C, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia [J]. Blood, 2011, 117(8): 2340-2347.
[8]	Te Winkel M L, Pieters R, Hop W C, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia[J].J Clin Oncol,2011,29(31):4143-4150.
[6]	Ganesan P, Thulkar S, Gupta R, et al. Childhood aleukemic leukemia with hypercalcemia and bone lesions mimicking metabolic bone disease [J]. J Pediatr Endocrinol Metab, 2009, 22(5): 463-467.
[9]	Fleisch H. Bisphosphonates: mechanisms of action [J]. Endocr Rev, 1998, 19 (1): 80-100.
[7]	Kawedia J D, Kaste S C, Pei D, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia [J]. Blood, 2011, 117(8): 2340-2347.
[10]	Padhye B, Dalla-Pozza L, Little DG, et al. Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis [J]. Pediatr Blood Cancer, 2013, 60(9): 1539-1545.
[8]	Te Winkel M L, Pieters R, Hop W C, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia[J].J Clin Oncol,2011,29(31):4143-4150.
[11]	Leblicq C, Laverdière C, Décarie J C, et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia [J]. Pediatr Blood Cancer, 2013, 60(5):741-747.
[9]	Fleisch H. Bisphosphonates: mechanisms of action [J]. Endocr Rev, 1998, 19 (1): 80-100.
[10]	Padhye B, Dalla-Pozza L, Little DG, et al. Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: a retrospective analysis [J]. Pediatr Blood Cancer, 2013, 60(9): 1539-1545.
[11]	Leblicq C, Laverdière C, Décarie J C, et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia [J]. Pediatr Blood Cancer, 2013, 60(5):741-747.